conservative management of ovarian cancer 14 5-2015
TRANSCRIPT
![Page 1: Conservative management of ovarian cancer 14 5-2015](https://reader031.vdocument.in/reader031/viewer/2022030223/588369df1a28ab536b8b5f49/html5/thumbnails/1.jpg)
![Page 2: Conservative management of ovarian cancer 14 5-2015](https://reader031.vdocument.in/reader031/viewer/2022030223/588369df1a28ab536b8b5f49/html5/thumbnails/2.jpg)
Ovarian cancer Sixth commonest cancer worldwide Fifth most frequent cause of cancer death The second most common gynecological cancer, after
endometrial cancer Approximately 1 in 70 newborn girls will develop
ovarian cancer during her lifetime 75% of women present with advanced disease Documented to occur in females of all ages.
![Page 3: Conservative management of ovarian cancer 14 5-2015](https://reader031.vdocument.in/reader031/viewer/2022030223/588369df1a28ab536b8b5f49/html5/thumbnails/3.jpg)
Origin of Ovarian Tumors
![Page 4: Conservative management of ovarian cancer 14 5-2015](https://reader031.vdocument.in/reader031/viewer/2022030223/588369df1a28ab536b8b5f49/html5/thumbnails/4.jpg)
Ovarian CancerHistologic Distribution
95%
4-5% ۱%
EpithelialGerm CellSex Cord Stroma
![Page 5: Conservative management of ovarian cancer 14 5-2015](https://reader031.vdocument.in/reader031/viewer/2022030223/588369df1a28ab536b8b5f49/html5/thumbnails/5.jpg)
Five year survival
![Page 6: Conservative management of ovarian cancer 14 5-2015](https://reader031.vdocument.in/reader031/viewer/2022030223/588369df1a28ab536b8b5f49/html5/thumbnails/6.jpg)
Stage Incidence
![Page 7: Conservative management of ovarian cancer 14 5-2015](https://reader031.vdocument.in/reader031/viewer/2022030223/588369df1a28ab536b8b5f49/html5/thumbnails/7.jpg)
Ovarian Cancer StagingStage I - Limited to ovaries
A. Unilateral ovaryB. Bilateral ovariesC. Positive cytology
Stage II - Limited to pelvis
A. Extends to uterus or tubesB. other pelvic organs
Stage III – Spread to upper abdomen or regional lymph nodes
A. Microscopic spread and/or Positive retroperitoneal lymph nodes B. Macroscopic < 2 cmC. Macroscopic > 2 cm
Stage IV - Spread outside peritoneum, pleura or parenchymal
![Page 8: Conservative management of ovarian cancer 14 5-2015](https://reader031.vdocument.in/reader031/viewer/2022030223/588369df1a28ab536b8b5f49/html5/thumbnails/8.jpg)
Ovarian Cancer Surgical Debulking and Staging
Exploration
Washings/Ascites
(Staging)
TAH/BSO
Biopsies(Staging)
Goals (Debulking)•Assessment of extent of disease
•Optimal tumor reduction
TAH = total abdominal hysterectomyBSO = bilateral salphingo-oophorectomy
![Page 9: Conservative management of ovarian cancer 14 5-2015](https://reader031.vdocument.in/reader031/viewer/2022030223/588369df1a28ab536b8b5f49/html5/thumbnails/9.jpg)
What is conservative? To an interventionist it might mean
Traditional Old fashioned Unprogressive
But it also means Careful, Cautious and Preserving Protecting Saving
![Page 10: Conservative management of ovarian cancer 14 5-2015](https://reader031.vdocument.in/reader031/viewer/2022030223/588369df1a28ab536b8b5f49/html5/thumbnails/10.jpg)
General PrincipleAny type of new managementwhich could impair the patients survival must not be employed if the “classic” treatments offer sure cure
![Page 11: Conservative management of ovarian cancer 14 5-2015](https://reader031.vdocument.in/reader031/viewer/2022030223/588369df1a28ab536b8b5f49/html5/thumbnails/11.jpg)
What is conservative surgery in Ovarian Cancer?
Unilateral salpingo-oophorectomy
Full surgical staging Washings Omentectomy Appendectomy Node biopsies A thorough abdominal exploration and biopsy of any abnormal areas Endometrial biopsy should be performed to exclude endometrial cancer
Do not biopsy the contralateral ovary
Adjuvant chemotherapy?
Simply it should be called Fertility Sparing Surgery (FSS)
![Page 12: Conservative management of ovarian cancer 14 5-2015](https://reader031.vdocument.in/reader031/viewer/2022030223/588369df1a28ab536b8b5f49/html5/thumbnails/12.jpg)
Sex cord - stromal tumors Malignant sex cord-stromal neoplasms are rare (1%)
Most commonly observed in postmenopausal period
Malignant neoplasms are generally considered to be low-grade
Disease was confined to the ovary in up to 95% of women
Conservative surgery is possible in a high percentage of young patients
Subsequent pregnancies have been documented only in case reports and small series (Powell et al)
![Page 13: Conservative management of ovarian cancer 14 5-2015](https://reader031.vdocument.in/reader031/viewer/2022030223/588369df1a28ab536b8b5f49/html5/thumbnails/13.jpg)
Germ cell tumors Account for only about 5% of all malignant ovarian
neoplasms
Arise primarily in young women between 10 and 30 years of age
Most OGCTs (60%) are stage I at initial presentation
Most patients can be safely treated with Conservative surgery rather than radical one
Highly sensitive to platinum-based chemotherapy
The survival in advanced disease is still over 90%
![Page 14: Conservative management of ovarian cancer 14 5-2015](https://reader031.vdocument.in/reader031/viewer/2022030223/588369df1a28ab536b8b5f49/html5/thumbnails/14.jpg)
Literature Review of Reproductive Function Following FSS for Malignant OGCT
Author No. Patients No. Normal menses No. Pregnancies
Greshenson 1988 40 27/40 (68%) 22 in 11
Brewer 1999 16 13/14 (93%) 5 in 3
Low 2000 74 43/47 (92%) 14 in 19
Zanetta 2001 138 80/81 (99%) 41 in 16
Tangir 2003 64 28/40 (69%) 47 in 29
Greshenson 2002 133 59/77 (77%) 37 in 38
![Page 15: Conservative management of ovarian cancer 14 5-2015](https://reader031.vdocument.in/reader031/viewer/2022030223/588369df1a28ab536b8b5f49/html5/thumbnails/15.jpg)
Ovarian tumors of low malignant potential
Account for 10–15% of all epithelial tumors
Good prognosis, with a 10-year survival of approximately 90%
The median age is 15–20 years younger than that for invasive epithelial ovarian tumors
60% to 90% are stage I
Conservative surgery is possible in a high proportion of young patients
![Page 16: Conservative management of ovarian cancer 14 5-2015](https://reader031.vdocument.in/reader031/viewer/2022030223/588369df1a28ab536b8b5f49/html5/thumbnails/16.jpg)
Literature Review of Pregnancies Following FSS for Tumors of Low Malignant Potential
Author No. Patients Stage No. Pregnancies
Lim-Tam 1988 35 IA-III 8
Gotlieb 1998 39 IA-III 22 in 15
Morris 2000 43 IA-III 25 in 12
Zanetta 2001 189 IA-III 44 in 44
Morris 2001 44 IA-III 17 in 14
![Page 17: Conservative management of ovarian cancer 14 5-2015](https://reader031.vdocument.in/reader031/viewer/2022030223/588369df1a28ab536b8b5f49/html5/thumbnails/17.jpg)
Invasive Epithelial Cancer The majority of ovarian malignancies (95%)
10-20 % of ovarian cancers occur before the age of 40 years.
The 5-year survival of patients with Stage IA, grade 1, EOC treated conservatively is 90%
Conservative surgery may be performed in selected young patients with apparent disease confined to one ovary
![Page 18: Conservative management of ovarian cancer 14 5-2015](https://reader031.vdocument.in/reader031/viewer/2022030223/588369df1a28ab536b8b5f49/html5/thumbnails/18.jpg)
Literature Review of Reproductive Function Following FSS for Invasive EOC
Author No. Patients Stage No.
Pregnancies No. Relapses
Colombo 1994 56 IA-IC 25 in 17 3
Zanetta 1997 56 IA-IC 27 in 20 5
Raspagliesi 1997 10 IA-III 3 in 3 0
Brown 1998 16 IA-IC 8 in 5 2
Morice 2001 25 IA-II 4 in 4 7
Schilder 2002 52 IA-IC 31 in 17 5
Kwon 2009 21 IA-IC 5 in 5 0
![Page 19: Conservative management of ovarian cancer 14 5-2015](https://reader031.vdocument.in/reader031/viewer/2022030223/588369df1a28ab536b8b5f49/html5/thumbnails/19.jpg)
Low risk group Stage IA G1-2 literature review
Author No. Patients
Stage and Grade No. relapses No. Death
Zanetta 1997 30 IA G1-2 3 1Morice 2001 19 IA G1-2 3 3Schilder 2002 42 IA 4 2Morice 2005 27 IA G1-2 5 2Borgfeldt 2007 10 IA G1-2 0 0Park 2008 32 IA G1-2 1 0Schlaerth 2009 11 IA 1 1Anchezar 2009 11 IA G1 2 1Kajiyama 2010 30 IA 2 2Satoh 2010 108 IA G1-2 5 1Fruscio 2013 115 IA G1-2 9 3Ditto 2014 8 IA G1-2 2 0
![Page 20: Conservative management of ovarian cancer 14 5-2015](https://reader031.vdocument.in/reader031/viewer/2022030223/588369df1a28ab536b8b5f49/html5/thumbnails/20.jpg)
High risk group Stage ≥ IAG3 literature review
Author No. Patients
Stage and Grade No. relapses No. Death
Raspagliesi 1997 10 > IA G1-2 0 0
Zanetta 1997 26 IA G3, IB, IC 2 2
Morice 2001 6 IC, II 4 NR
Schilder 2002 10 IC 1 0
Morice 2005 7 IA G3, IC,IIA 5 2
Borgfeldt 2007 1 IC G3 1 0
Park 2008 30 IA G3-IIIC 10 6
Schlaerth 2009 9 IC 2 2
Anchezar 2009 7 IC – IIIB 1 0
Kajiyama 2010 30 IB-IC 6 5
Satoh 2010 103 IA G3, IC 13 4
Fruscio 2013 125 IA G3-IIB 18 8
Ditto 2014 10 > IA G1-2 2 0
![Page 21: Conservative management of ovarian cancer 14 5-2015](https://reader031.vdocument.in/reader031/viewer/2022030223/588369df1a28ab536b8b5f49/html5/thumbnails/21.jpg)
![Page 22: Conservative management of ovarian cancer 14 5-2015](https://reader031.vdocument.in/reader031/viewer/2022030223/588369df1a28ab536b8b5f49/html5/thumbnails/22.jpg)
Sait et. al. Local Series A retrospective study of women conservatively treated for
primary ovarian cancer between January 2000 and December 2010 at King Abdulaziz University Hospital
39 patients 80% were stage I 52% were Germ cell tumor 8% patients had recurrent disease 20% had a normal pregnancy
![Page 23: Conservative management of ovarian cancer 14 5-2015](https://reader031.vdocument.in/reader031/viewer/2022030223/588369df1a28ab536b8b5f49/html5/thumbnails/23.jpg)
![Page 24: Conservative management of ovarian cancer 14 5-2015](https://reader031.vdocument.in/reader031/viewer/2022030223/588369df1a28ab536b8b5f49/html5/thumbnails/24.jpg)
Indications for FSS in ovarian cancer
Nonepithelial ovarian cancers
Ovarian tumors of low malignant potential
Early stage Epithelial ovarian carcinoma Stage IA G1-2
![Page 25: Conservative management of ovarian cancer 14 5-2015](https://reader031.vdocument.in/reader031/viewer/2022030223/588369df1a28ab536b8b5f49/html5/thumbnails/25.jpg)
Future Perspectives The merged role of the treating physician as both life-save and
protector-of- future fertility has made the field of oncofertility a substantial part of gynecologic oncology nowadays
Prospectively designed and RCTs to evaluate safety of FSS are neither possible nor ethical
Our experience in outcomes after FSS mainly originates from retrospective case series
The gynecologic oncologist is in a unique position to provide young cancer patients with up-to-date fertility preservation information and fertility-sparing surgical alternatives
There is a need of close collaboration between cancer centers and reproductive centers in these cases
![Page 26: Conservative management of ovarian cancer 14 5-2015](https://reader031.vdocument.in/reader031/viewer/2022030223/588369df1a28ab536b8b5f49/html5/thumbnails/26.jpg)
Conclusion After thorough insight of the current literature, FSS in
certain ovarian tumors appears a viable and safe option for women younger than 40 years who wish to preserve their childbearing potential
Only after thorough discussion and informed consent with careful balancing of the risks and benefits
The treating gynecologic oncologist should be fully aware of his double role in treating the malignant disease as well as in providing oncofertility care to young patients, by offering fertility-sparing alternatives when allowed so by tumor stage and histologic differentiation
![Page 27: Conservative management of ovarian cancer 14 5-2015](https://reader031.vdocument.in/reader031/viewer/2022030223/588369df1a28ab536b8b5f49/html5/thumbnails/27.jpg)
Thank you